Saturday 17 October 2026
Export XENE’s income statement to Excel — free account
Xenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022. In the quarter to June 2026, revenue grew 100.7%, EPS fell 3.74% and free cash flow fell 48.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
33.55
0.78
−2.27%
Follow XENE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.14%) | (51.76%) | (37.53%) | (43.62%) | |
| (42.44%) | (48.34%) | (35.98%) | (41.54%) | ||
ROIC |
(219.03%) | (709.28%) | (106.11%) | (88.54%) | |
Return on Tangible Assets |
(67.97%) | (65.57%) | (35.64%) | (45.03%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.20) | (3.53) | (3.52) | (3.40) | |
Free Cash Flow |
(253.29) | (279.92) | (307.25) | (338.53) | |
Capital Expenditures |
(1.26) | (0.80) | (0.89) | (1.01) | |
| Other line items | |||||
Cash ROIC |
(24.79%) | (24.76%) | (12.63%) | (15.58%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | 0.00 | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 0.81 | 0.80 | 0.82 | |
Depreciation/Fixed assets |
0.29 | 0.29 | 0.30 | 0.31 | |
Capex/Depreciation |
(0.49) | (0.31) | (0.36) | (0.42) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.18) | (3.52) | (3.51) | (3.39) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates